Results 221 to 230 of about 45,696 (262)

Use of Ceftazidime-Avibactam and Ceftolozane-Tazobactam After Lung Transplantation

Transplantation Proceedings, 2020
After lung transplantation (LTx), infections caused by multidrug-resistant (MDR) bacteria are frequent and difficult to treat. Some new antibiotics seem to be effective in treating these infections.We describe our experience in treatment of Klebsiella pneumoniae MDR and Pseudomonas aeruginosa MDR infections with ceftazidime-avibactam (CEF-AVI) and ...
Amore D., Pecoraro Y., Carillo C., Russo G., Poggi C., Anile M., Pagini A., Bassi M., Cagnetti S., Mottola E., D'Agostino F. G., Vannucci J., Mantovani S., Pugliese F., De Giacomo T., Rendina E. A., Venuta F., Diso D.   +17 more
openaire   +2 more sources

Therapeutic insights: Use of ceftazidime‐avibactam in pediatric patients

Pediatrics International
Abstract Background The increasing worldwide prevalence of multidrug‐resistant (MDR) bacteria underscores the pressing demand for innovative therapeutic solutions. Ceftazidime‐avibactam (CAZ‐AVI) represents a promising new drug combination that has received approval for specific infection types.
Özge Metin Akcan, Mustafa Gençeli, Talha Üstüntaş, Abdullah Akkuş, Sevgi Pekcan, Metin Doğan   +5 more
openaire   +2 more sources

An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patients.

Journal of Antimicrobial Chemotherapy
OBJECTIVES Ceftazidime/avibactam is a key antibiotic for carbapenemase-producing Enterobacterales (CPE) Gram-negative infections, but current dosing may be suboptimal to grant activity. This study explores the population pharmacokinetics/pharmacodynamics
P. Cojutti, Manjunath P. Pai, Milo Gatti, M. Rinaldi, S. Ambretti, P. Viale, F. Pea   +6 more
semanticscholar   +1 more source

The pharmacokinetics/pharmacodynamics of ceftazidime/avibactam for central nervous system infections caused by carbapenem-resistant Gram-negatives: a prospective study.

Journal of Antimicrobial Chemotherapy
OBJECTIVES To describe the pharmacokinetics/pharmacodynamics (PK/PD) of ceftazidime/avibactam in critically ill patients with CNS infections. METHODS A prospective study of critically ill patients with CNS infections who were treated with ceftazidime ...
Ying Xu, Xuemei Luo, Binbin Yuan, Pei Liang, Ning Liu, Danjiang Dong, Weihong Ge, Qin Gu   +7 more
semanticscholar   +1 more source

Sequential Treatment Failure With Aztreonam-Ceftazidime-Avibactam Followed by Cefiderocol Due to Preexisting and Acquired Mechanisms in a New Delhi Metallo-β-lactamase-Producing Escherichia coli Causing Fatal Bloodstream Infection.

Clinical Infectious Diseases
We report a fatal case of New Delhi metallo-β-lactamase (NDM)-producing Escherichia coli in a bacteremic patient with sequential failure of aztreonam plus ceftazidime-avibactam followed by cefiderocol.
Fiona Senchyna, K. Murugesan, William Rotunno, S. Nadimpalli, Stan Deresinski, Niaz Banaei   +5 more
semanticscholar   +1 more source

Mechanisms and fitness of ceftazidime/avibactam-resistant Klebsiella pneumoniae clinical strains in Taiwan.

International Journal of Antimicrobial Agents
BACKGROUND Carbapenem-resistant Klebsiella pneumoniae (CRKP) infection is a global public health issue, and ceftazidime/avibactam is recommended by international guidelines as the preferred treatment for KPC- and OXA-48-producing CRKP.
Sheng-Hua Chou, Chien Chuang, Chih-Han Juan, Yu-Chien Ho, Szu- Yu Liu, Liang Chen, Yi-Tsung Lin   +6 more
semanticscholar   +1 more source

Complex evolutionary trajectories in vivo of two novel KPC variants conferring ceftazidime-avibactam resistance.

International Journal of Antimicrobial Agents
More and more ceftazidime-avibactam resistant KPC-producing K. pneumoniae have been reported with its widespread use, and the detection rate of KPC variants has increased dramatically.
Chengkang Tang, S. Shen, Weiwei Yang, Qingyu Shi, Li Ding, Renru Han, D. Yin, Yan Guo, Demei Zhu, F. Hu   +9 more
semanticscholar   +1 more source

The prevalence and mechanisms of heteroresistance to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae.

Journal of Antimicrobial Chemotherapy
OBJECTIVES To investigate the prevalence and mechanisms of ceftazidime/avibactam heteroresistance in KPC-producing Klebsiella pneumoniae (KPC-KP) isolates, as well as the role of heteroresistance in the transition of ceftazidime/avibactam susceptibility ...
Xiaotuan Zhang, Weiliang Zeng, Ji-Hye Kong, Zeyu Huang, Hongyun Shu, Miran Tang, Changrui Qian, Chunquan Xu, Tieli Zhou, Jianzhong Ye   +9 more
semanticscholar   +1 more source

Renal Function and Its Impact on the Concentration of Ceftazidime-Avibactam: A cross-sectional study.

International Journal of Antimicrobial Agents
OBJECTIVES This study measured the effect of renal function on the plasma concentrations of ceftazidime and avibactam in critically ill patients. We also sought to measure the concentration ratio of ceftazidime to avibactam.
S. Lanini, Simone Giuliano, Jacopo Angelini, S. Ferin, Luca Martini, Massimo Baraldo, Stella Cossettini, Jason Roberts, C. Tascini   +8 more
semanticscholar   +1 more source

Studying ceftazidime-avibactam in selected populations

The Lancet Infectious Diseases, 2016
Florian M E, Wagenlehner, Kurt G, Naber
openaire   +2 more sources